Aptar has announced its acquisition of Noble International, which specializes in training devices and patient onboarding for drug delivery devices, including inhalers. Noble makes respiratory trainers for both MDIs and DPIs with a variety of technologies including Bluetooth connectivity, actuation force simulation, and error detection/correction. According to … [Read more...] about Aptar acquires training device company Noble International
News
Liquidia adds Katie Rielly-Gauvin to its board of directors
Liquidia Technologies has announced the appointment of AbbVie VP of Global Commercial Development Katie Rielly-Gauvin to its board of directors for a term that will extend until company's 2020 annual meeting. Prior to her position at AbbVie, Rielly-Gauvin held various executive positions at Johnson & Johnson companies over a number of therapeutic areas. In … [Read more...] about Liquidia adds Katie Rielly-Gauvin to its board of directors
Aradigm withdraws Linhaliq MAA
After having been notified that CHMP was likely to issue a negative opinion regarding its MAA for Linhaliq dual release inhaled ciprofloxacin for the treatment of P. aeruginosa lung infections in patients with non-cystic fibrosis bronchiectasis (NCFBE), Aradigm has withdrawn the application. The company initially submitted the MAA in March 2018. Aradigm filed for … [Read more...] about Aradigm withdraws Linhaliq MAA
Third Pole Therapeutics names Bill Athenson as CEO
Inhaled nitric oxide developer Third Pole Therapeutics has announced the appointment of Bill Athenson as its new Chief Executive Officer, succeeding founding CEO David Zapol. Athenson most recently served as CEO of Three Lakes Partners; his previous experience includes 13 years as the VP, Global Sales, Marketing and Business Development at Nanosphere Inc. In … [Read more...] about Third Pole Therapeutics names Bill Athenson as CEO
Vectura names Will Downie as CEO and Executive Director
Inhaled drug developer Vectura has announced the appointment of former Catalent executive Will Downie as CEO and Executive Director. Downie was most recently Senior VP, Global Sales and Marketing at Catalent and previously served in various roles at GE Healthcare, Amersham Health, and Quintiles. In July 2019, Vectura announced that it would focus its R&D … [Read more...] about Vectura names Will Downie as CEO and Executive Director
Micro-Sphere to add spray drying capacity
CDMO Micro-Sphere has announced an investment of 3.5 million CHF (~$3.5 million) that will include the addition of a fifth spray drying line to its GMP facility in Switzerland. The new line should be in operation by the first quarter of 2021. According to the company, the expansion is needed due to increased demand for both spray drying and capsule filling for DPIs. … [Read more...] about Micro-Sphere to add spray drying capacity
Iconovo to develop generic Ellipta DPI platform
Dry powder inhaler developer Iconovo has announced that the company will invest approximately 20 million SEK over about 3 years to develop a new platform for development of generic versions of Ellipta DPI products. The platform will include a new device called ICOpre and custom dry powder formulations that will be pre-filled. The company said that the generic … [Read more...] about Iconovo to develop generic Ellipta DPI platform
Bryn Pharma raises $17.5 million to fund regulatory and commercial activities for its epinephrine nasal spray
Bryn Pharma, which recently announced that it would use Aptar's Bidose nasal device for delivery of its BRYN-NDS1C intranasal epinephrine, said that it has raised $17.5 million that it will use to prepare for US regulatory approval and commercialization of the nasal spray. BRYN-NDS1C has received Fast Track designation from the FDA, and the company plans to pursue … [Read more...] about Bryn Pharma raises $17.5 million to fund regulatory and commercial activities for its epinephrine nasal spray
TFF Pharmaceuticals announces IPO
TFF Pharmaceuticals, which is developing DPI formulations based on its thin film freezing (TFF) technology, has announced an initial public offering of 4,400,000 shares of common stock at $5.00 per share. Earlier this year TFF announced that it had raised $8.17 million through a Series A preferred stock offering. The company said that it expects to use the net … [Read more...] about TFF Pharmaceuticals announces IPO
Studies show Penthrox is superior to standard of care for acute trauma pain
Medical Developments International (MDI) has announced data from multiple European studies demonstrating the benefits of MDI's Penthrox methoxyflurane inhaler for the treatment of pain from acute trauma. Among the findings announced, Penthrox was shown to be superior to intravenous morphine, NSAIDS, paracetamol (acetaminophen), and ketoprofen in trauma settings; … [Read more...] about Studies show Penthrox is superior to standard of care for acute trauma pain